Phase II Clinical Trial of Genexol (Paclitaxel) and Carboplatin for Patients with Advanced Non-small Cell Lung Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose This phase II clinical trial was conducted to evaluate the activity and safety of a combination treatment of paclitaxel (Genexol) plus carboplatin in patients with advanced non-small cell lung cancer. Materials and Methods Chemotherapy-naïve patients having histologically confirmed advanced or metastatic nonsmall cell lung cancer were enrolled. Genexol was administered at 225 mg/m2 intravenous (IV) infusion over 3 hours, followed by carboplatin (area under the concentration-time curve=6) IV on day 1 every 3 weeks. Results Twenty-eight patients were enrolled between January 2003 and January 2005. A total of 110cycles of chemotherapy were given. The median number of chemotherapy cycles was 4. A total of 25 study patients were evaluable. On an intent-to-treat basis, there were ten partial responses (response rate 35.7%). The median time-to-progression was 3.2 months (95%confidence interval [CI], 1.5 to 4.9) and the median overall survival was 8.2 months (95% CI,4.1 to 12.3). The main hematologic grade 3/4 toxicity was neutropenia, which was observed in 14 (50.0%) patients. The main non-hematologic toxicity was peripheral neuropathy, which was observed in 12 patients (42.9%). Grade 3/4 neuropathy occurred in 8 patients (28.6%)and three patients discontinued treatment because of neuropathy. Conclusion In this trial, the combination of Genexol and carboplatin showed significant activity as first line treatment for patients with advanced or metastatic non-small cell lung cancer. However,a modest dose reduction of Genexol is needed due to sensory neuropathy.
Abstract
Purpose This phase II clinical trial was conducted to evaluate the activity and safety of a combination treatment of paclitaxel (Genexol) plus carboplatin in patients with advanced non-small cell lung cancer. Materials and Methods Chemotherapy-naïve patients having histologically confirmed advanced or metastatic nonsmall cell lung cancer were enrolled. Genexol was administered at 225 mg/m2 intravenous (IV) infusion over 3 hours, followed by carboplatin (area under the concentration-time curve=6) IV on day 1 every 3 weeks. Results Twenty-eight patients were enrolled between January 2003 and January 2005. A total of 110cycles of chemotherapy were given. The median number of chemotherapy cycles was 4. A total of 25 study patients were evaluable. On an intent-to-treat basis, there were ten partial responses (response rate 35.7%). The median time-to-progression was 3.2 months (95%confidence interval [CI], 1.5 to 4.9) and the median overall survival was 8.2 months (95% CI,4.1 to 12.3). The main hematologic grade 3/4 toxicity was neutropenia, which was observed in 14 (50.0%) patients. The main non-hematologic toxicity was peripheral neuropathy, which was observed in 12 patients (42.9%). Grade 3/4 neuropathy occurred in 8 patients (28.6%)and three patients discontinued treatment because of neuropathy. Conclusion In this trial, the combination of Genexol and carboplatin showed significant activity as first line treatment for patients with advanced or metastatic non-small cell lung cancer. However,a modest dose reduction of Genexol is needed due to sensory neuropathy.
참고문헌 (10)
- 2007 Annual report of the Korea Cancer Registration, "Ministry for Health, Welfare and Family Affairs, Headquarters of Central Cancer Registry", Ministry for Health, Welfare and Family Affairs, ~ (2009)
- Schiller JH, "Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer", N Engl J Med, 346, pp.92~98 (2002)
- Kelly K, "Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial", J Clin Oncol, 19, pp.3210~3218 (2001)
- Se-Hoon Lee, "A Multi-Center, Phase II Clinical Trial of Genexol (Paclitaxel) and Cisplatin for Patients with Non-SmallCell Lung Cancer", Cancer Research and Treatment, 35(1), pp.30~34 (2003), 대한암학회
- Oken MM, "Toxicity and response criteria of the Eastern Cooperative Oncology Group", Am J Clin Oncol, 5, pp.649~655 (1982)
- Smit EF, "Threearm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer. A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group: EORTC 08975", J Clin Oncol, 21, pp.3909~3917 (2003)
- Scagliotti GV, "Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer", J Clin Oncol, 26, pp.3543~3551 (2008)
- Kosmidis P, "Paclitaxel (175 mg", m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg, Ann Oncol, pp.2000, 11[DOI]
- Morère JF, "Dosefinding study of paclitaxel and carboplatin in patients with advanced non-small cell lung cancer", Anticancer Drugs, 11, pp.541~548 (2000)
- Huizing MT, "Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dosesequencing study in patients with non-small-cell lung cancer: the European Cancer Centre", J Clin Oncol, 15, pp.317~329 (1997)